DC Circ. Revives K-V's FDA Enforcement Row

Law360, New York (January 9, 2014, 3:55 PM EST) -- The D.C. Circuit on Tuesday revived K-V Pharmaceutical Co.'s suit attempting to force the U.S. Food and Drug Administration to block pharmacies from producing cheaper compounded versions of K-V's preterm-birth prevention drug Makena.

In a brief order, a three-judge panel for the appeals court vacated a September 2012 order by U.S. District Judge Amy Berman Jackson that had dismissed the suit. Judge Jackson’s ruling found that the FDA's enforcement actions are immune from judicial review unless Congress specifically intended in a statute to curb the agency's...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

K-V Pharmaceutical Company, et al v. FDA, et al


Case Number

12-5349

Court

Appellate - DC Circuit

Nature of Suit

2890 Other Statutory Actions

Date Filed

November 8, 2012

Law Firms

Companies

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.